Real-Life Examples of Post-Marketing Surveillance in Clinical Trials

Part of Fundamentals of Clinical Research: Pharmacovigilance and Safety.

About 3 minutes. Free, in your language, no account needed.

Chapter: Real-Life Examples of Post-Marketing Surveillance in Clinical Trials

Post-marketing surveillance is a critical aspect of clinical trials that allows for monitoring the safety and efficacy of drugs or medical devices once they have been approved and are on the market. In this chapter, we will explore real-life examples of post-marketing surveillance to understand its importance in ensuring the health and well-being of patients.

Example 1: Thalidomide

One of the most well-known cases of post-marketing surveillance is the tragic story of thalidomide. In the late 1950s and early 1960s, thalidomide was marketed as a sedative and anti-nausea medication for pregnant women. However, it was later discovered that thalidomide caused severe birth defects in babies whose mothers had taken the drug during pregnancy. This example highlights the importance of post-marketing surveillance in identifying unexpected side effects and ensuring patient safety.

Example 2: Vioxx

Vioxx, a nonsteroidal anti-inflammatory drug (NSAID) used to treat pain, was approved by the FDA in 1999. However, in 2004, the drug was withdrawn from the market due to an increased risk of heart attacks and strokes in patients taking the medication. Post-marketing surveillance played a crucial role in uncovering these safety concerns and ultimately led to the withdrawal of Vioxx to protect patients from harm.

Example 3: Essure

Essure was a permanent birth control device that was approved by the FDA in 2002. However, reports of serious side effects, including perforation of the uterus and migration of the device, led to increased scrutiny of Essure through post-marketing surveillance. In 2018, the FDA restricted the sale and distribution of Essure after determining that the risks outweighed the benefits. This case illustrates how post-marketing surveillance can prompt regulatory action to safeguard patient health.

These real-life examples demonstrate the importance of post-marketing surveillance in identifying potential safety issues with drugs and medical devices after they have been approved for use. By continuously monitoring and assessing the real-world impact of these products, researchers and regulators can take proactive measures to protect patients and improve public health.

Related Resources:

1. FDA's MedWatch Program: Provides information on reporting adverse events and safety concerns related to drugs, medical devices, and biological products.
2. European Medicines Agency (EMA) Pharmacovigilance: Offers guidance on post-marketing surveillance and pharmacovigilance activities in Europe.
3. World Health Organization (WHO) Global Individual Case Safety Reports: Provides information on global efforts to monitor and report individual case safety reports for pharmaceutical products worldwide.

In conclusion, post-marketing surveillance is essential for detecting and addressing safety concerns associated with drugs and medical devices in real-world settings. By learning from past examples and utilizing available resources, we can strive to improve patient outcomes and promote public health through effective post-marketing surveillance practices.